HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 2,545-2,556 of 4,505
Other study type icon
CompletedNCT00686101

Knowledge and Perception of Smoking Risks/Consequences

Official study title

Knowledge and Perception of Smoking Risks/Consequences, Smoking Habits and Motivators for Smoking Cessation Among People With Schizophrenia

This study has finished and is no longer accepting participants.

In Baltimore
SchizophreniaObservational studyAges 18–65
Countries
United States
Sponsor
University of Maryland, Baltimore
Drug study icon
CompletedNCT00718510

L-arginine in Treatment as Usual in Schizophrenia

Official study title

A Randomised, Double-blind, Cross-over, Placebo Controlled, Adjunctive-treatment of L-arginine Added to Treatment-as-usual (TAU) in Schizophrenia

This study has finished and is no longer accepting participants.

In Edmonton
SchizophreniaMedication studyAges 18–65
Countries
Canada
Sponsor
University of Alberta
Other study type icon
CompletedNCT00372151

L-Theanine in the Management of Schizophrenia

Official study title

The Value of Augmenting L-Theanine in the Management of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

This study has finished and is no longer accepting participants.

Multiple locations, including Beersheba
SchizophreniaPlacebo comparisonAges 18–60
Countries
Israel
Sponsor
Sha'ar Menashe Mental Health Center
Drug study icon
TerminatedNCT00947375

Lamictal TM, Haloperidol Decanoate in Schizophrenia

Official study title

The Effect of Lamictal TM Augmentation of Haloperidol Decanoate in the Treatment of Resistant Schizophrenia Predominantly by Verbal Resistant Hallucinosis: Randomized, Double-blind, Placebo-controlled, Study

This study ended early.

In Baku
SchizophreniaMedication studyAges 18–60
Countries
Azerbaijan
Sponsor
Central Mental Clinic for Outpatients of Baku City
Behavioral study icon
CompletedNCT01368406

Lifestyle Intervention for Weight Gain Management for people with Schizophrenia

Official study title

Efficacy of a Non-pharmacological Intervention for Weight Gain Management for Patients With Schizophrenia: Multicentric, Randomized Clinical Trial

This study has finished and is no longer accepting participants.

In São Paulo
SchizophreniaBehavioural studyAges 18–65
Countries
Brazil
Sponsor
Federal University of São Paulo
Drug study icon
TerminatedNCT01943019

Linagliptin in Schizophrenia Patients

What is this study about?

Researchers are studying Linagliptin to find out how it affects psychotic symptoms in people with schizophrenia.

This study ended early.

In Bandar Tun Razak
SchizophreniaMedication studyAges 18–65
Countries
Malaysia
Sponsor
Monash University
Drug study icon
CompletedNCT02203838

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

What is this study about?

Researchers studied RBP-7000, tracking side effects to assess long-term safety and tolerability in people with schizophrenia.

This study has finished and is no longer accepting participants.

Multiple locations, including Little Rock
SchizophreniaMedication studyAges 18–65
Countries
United States
Sponsor
Indivior Inc.
Drug study icon
CompletedNCT00216671

Long-acting Injectable Risperidone in people with Schizophrenia After an Acute Episode

Official study title

Early Versus Late Initiation of Treatment With Risperdal Consta in Subjects With Schizophrenia After an Acute Episode

This study has finished and is no longer accepting participants.

Multiple locations, including Copenhagen
SchizophreniaMedication studyAges 18–65
Countries
France, United Kingdom, Switzerland, + 7 others
Sponsor
Janssen Pharmaceutica N.V., Belgium
Drug study icon
CompletedNCT02918825

Long-acting Paliperidone Palmitate Injection and Olanzapine for Schizophrenia

Official study title

A Randomized Trial to Compare the Efficiency and Side Effect Between Olanzapine and Long-acting Paliperidone Palmitate Injection in Schizophrenia

This study has finished and is no longer accepting participants.

In Beijing
SchizophreniaMedication studyAges 18–45
Countries
China
Sponsor
Beijing HuiLongGuan Hospital

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.